Cannabidiol for epilepsy: trying to see through the haze

The Lancet Neurology

Volumn 15, Issue 3, 2016, Pages 235-237

  Detyniecki, Kamil ^a   Hirsch, Lawrence J ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CANNABIDIOL; CANNABINOID RECEPTOR; MEDICAL CANNABIS;

ANTICONVULSANT ACTIVITY; BRAIN DEVELOPMENT; CANNABIS USE; COGNITIVE DEFECT; CONVULSION; DECREASED APPETITE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG RESISTANT EPILEPSY; EPILEPSY; EPILEPTIC STATE; FATIGUE; HUMAN; LENNOX GASTAUT SYNDROME; NOTE; PRIORITY JOURNAL; QUALITY OF LIFE; SEIZURE; SEVERE MYOCLONIC EPILEPSY IN INFANCY; SOCIAL MEDIA; SOMNOLENCE; EPILEPSIES, MYOCLONIC; FEMALE; MALE; OUTCOME ASSESSMENT; SEIZURES;

ANTICONVULSANTS; CANNABIDIOL; DRUG RESISTANT EPILEPSY; EPILEPSIES, MYOCLONIC; FEMALE; HUMANS; LENNOX GASTAUT SYNDROME; MALE; OUTCOME ASSESSMENT (HEALTH CARE); SEIZURES;

EID: 84981523690     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(16)00002-8     Document Type: Note

References (10)

1. 1 Devinsky, O, Cilio, MR, Cross, H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 55 (2014), 791–802.
2. 2 Pertwee, RG, The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153 (2008), 199–215.
3. 3 Detyniecki, K, Hirsch, L, Marijuana use in epilepsy: the myth and the reality. Curr Neurol Neurosci Rep 15 (2015), 1–6.
4. 4 Koppel, BS, Brust, JC, Fife, T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 82 (2014), 1556–1563.
5. 5 American Epilepsy Society. AES position on medical marijuana. https://www.aesnet.org/about_aes/position_statements/AES%20Position%20on%20Medical%20Marijuana, Feb 28, 2014 (accessed Dec 17, 2015).
6. 6 Devinsky, O, Marsh, E, Friedman, D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional study. Lancet Neurol, 2015 published online Dec 23. http://dx.doi.org/10.1016/S1474-4422(15)00379-8.
7. 7 Press, CA, Knupp, KG, Chapman, KE, Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav 45 (2015), 49–52.
8. 8 Geffrey, AL, Pollack, SF, Bruno, PL, Thiele, EA, Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia 56 (2015), 1246–1251.
9. 9 Volkow, ND, Baler, RD, Compton, WM, Weiss, SR, Adverse health effects of marijuana use. N Engl J Med 370 (2014), 2219–2227.
10. 10 Zalesky, A, Solowij, N, Yucel, M, et al. Effect of long-term cannabis use on axonal fibre connectivity. Brain 135 (2012), 2245–2255.